Dr. Lisa S. Wang, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
12462 Putnam St, Ste 206
Whittier, CA 90602
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 344
Licensed in California since 2006, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A98434 (first issued 2006; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Pih Health Hospital-Whittier Whittier, CA
- Pih Health Downey Hospital Downey, CA
Medical groups
- Pih Health Physicians (622 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 344
- Services billed
- 35,530
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 3,060 | 20 |
| Injection of drug or substance under skin or into muscle | 851 | 111 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 558 | 90 |
| Established patient office or other outpatient visit, 30-39 minutes | 350 | 188 |
| Established patient office or other outpatient visit, 20-29 minutes | 265 | 158 |
| Established patient office or other outpatient visit, 40-54 minutes | 258 | 93 |
| Collection of blood sample from implanted device | 164 | 28 |
| Insertion of needle into vein for collection of blood sample | 104 | 60 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 65 | 23 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 61 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Whittier, CA | 252 |
| Eliquis (apixaban) Other prescribers in Whittier, CA | 209 |
| Letrozole Other prescribers in Whittier, CA | 96 |
| Alendronate Sodium Other prescribers in Whittier, CA | 96 |
| Raloxifene Hcl Other prescribers in Whittier, CA | 77 |
| Levothyroxine Sodium Other prescribers in Whittier, CA | 74 |
| Tamoxifen Citrate Other prescribers in Whittier, CA | 74 |
| Ondansetron Odt (ondansetron) Other prescribers in Whittier, CA | 42 |
| Cyanocobalamin Injection (cyanocobalamin (vitamin b-12)) Other prescribers in Whittier, CA | 37 |
| Furosemide Other prescribers in Whittier, CA | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 43 payments worth $1,087 in total to this clinician.
| Merck Sharp & Dohme LLC | $263 |
|---|---|
| Novartis Pharmaceuticals Corporation | $150 |
| Beone Medicines USA, Inc. | $110 |
| Pfizer Inc. | $87.00 |
| AbbVie Inc. | $74.34 |
| Janssen Biotech, Inc. | $67.36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $49.36 |
| Takeda Pharmaceuticals U.S.A., Inc. | $41.68 |
| Food and Beverage | $1,054 |
|---|---|
| Education | $32.72 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Jul 9, 2025 | Education in-kind | $32.72 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $197,502 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overe…
Amgen Inc. - A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo Inc. · Recruiting · NCT06330064 - Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC - Ultrasound-Guided Erector Spinae Plane Block Following Upper Extremity Surgery
Ipsen Bioscience Inc. · Withdrawn · NCT04083274 - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company · Active, not recruiting · NCT05288166 - A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
AstraZeneca Pharmaceuticals LP - Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06
Genentech, Inc. - Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
Daiichi Sankyo Inc. · Active, not recruiting · NCT04656652
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.